Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 693-702 , May 2011

Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen

  • Joanna M. Schaenman

      Affiliations

    • Division of Infectious Diseases, Stanford University Medical Center, Stanford, California
    • Corresponding Author InformationCorrespondence and reprint requests: Joanna M. Schaerman, MD, PhD, Division of Infectious Deseases, Stanford University School of Medicine, Stanford, CA 94305-5623.
    • ,
  • Sumana Shashidhar

      Affiliations

    • Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California
    • ,
  • Chanu Rhee

      Affiliations

    • Department of Medicine, Stanford University Medical Center, Stanford, California
    • ,
  • Jonathan Wong

      Affiliations

    • Division of Infectious Diseases, Stanford University Medical Center, Stanford, California
    • ,
  • Shelly Navato

      Affiliations

    • Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California
    • ,
  • Ruby M. Wong

      Affiliations

    • Department of Health Research and Policy, Stanford University Medical Center, Stanford, California
    • ,
  • Dora Y. Ho

      Affiliations

    • Division of Infectious Diseases, Stanford University Medical Center, Stanford, California
    • ,
  • Sally Arai

      Affiliations

    • Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California
    • ,
  • Laura Johnston

      Affiliations

    • Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California
    • ,
  • Janice M. Brown

      Affiliations

    • Division of Infectious Diseases, Stanford University Medical Center, Stanford, California
    • Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California

Received 9 July 2010 ,Accepted 16 August 2010.

References 

  1. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9:543–558
  2. Lilleri D, Fornara C, Chiesa A, Caldera D, Alessandrino EP, Gerna G. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica. 2008;93:248–256
  3. Hakki M, Riddell SR, Storek J, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood. 2003;102:3060–3067
  4. Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood. 2001;97:1232–1240
  5. Lowsky R, Takahashi T, Liu PL, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med. 2005;353:1321–1331
  6. Kohrt HE, Turnbull BB, Heydari K, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009;114:1099–1109
  7. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood. 2002;99:1978–1985
  8. Nakamae H, Kirby KA, Sandmaier BM, et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009;15:694–703
  9. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88:4063–4071
  10. Yanada M, Yamamoto K, Emi N, et al. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;32:801–807
  11. Schetelig J, Oswald O, Steuer N, et al. Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia. Bone Marrow Transplant. 2003;32:695–701
  12. Mohty M, Faucher C, Vey N, et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant. 2000;26:251–255
  13. Mohty M, Jacot W, Faucher C, et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia. 2003;17:2168–2177
  14. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99:4357–4363
  15. Park SH, Choi SM, Lee DG, et al. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin. Transplant Infect Dis. 2009;11:413–423
  16. Juliusson G, Theorin N, Karlsson K, Frodin U, Malm C. Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplant. 2006;37:503–510
  17. Einsele H, Kapp M, Grigoleit GU. CMV-specific T cell therapy. Blood Cells Mol Dis. 2008;40:71–75
  18. Foster AE, Gottlieb DJ, Sartor M, Hertzberg MS, Bradstock KF. Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:501–511
  19. Moins-Teisserenc H, Busson M, Scieux C, et al. Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation. J Infect Dis. 2008;198:818–826
  20. Pass RF, Stagno S, Britt WJ, Alford CA. Specific cell-mediated immunity and the natural history of congenital infection with cytomegalovirus. J Infect Dis. 1983;148:953–961
  21. Tu W, Chen S, Sharp M, et al. Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. J Immunol. 2004;172:3260–3267
  22. Hassan J, Dolley S, Hall W. Immunological response to cytomegalovirus in congenitally infected neonates. Clin Exp Immunol. 2007;147:465–471
  23. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood. 1994;83:1971–1979
  24. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008;300:413–422

 Financial disclosure: See Acknowledgments on page 701.

PII: S1083-8791(10)00349-6

doi: 10.1016/j.bbmt.2010.08.010

Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 693-702 , May 2011

Article Tools

* Image Usage & Resolution